Dako announced in mid-February that the company has entered into a collaboration agreement with Pfizer in the field of companion diagnostics.
The agreement constitutes a legal framework for various collaboration projects between the two companies, covering research, development and commercialization as well as advisory services.
“We are extremely excited to partner with Pfizer, a company with such a global presence and reputation for market leadership. This collaboration is testimony to the level of expertise and service Dako is committed to delivering to our partners in companion diagnostics,” said Lars Holmkvist, CEO of Dako and senior vice president, Agilent in a press release.
The news follows an earlier announcement from Dako introducing a framework agreement between Dako and Eli Lilly and Company, which focuses on developing novel companion diagnostics for Eli Lilly’s oncology pipeline.
Financial terms of the new agreement were not disclosed.